Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZP-01
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Peptides
01
Overview
**AZP-01** is a peptide derived from unacylated ghrelin (UAG), developed as a growth hormone secretagogue by Alize Pharma for metabolic indications. It targets improvements in glucose metabolism, endocrine pancreatic function, appetite stimulation, and cardiovascular effects, addressing needs in type 2 diabetes where lowering HbA1c alone is insufficient without cardiovascular benefits. The program focuses on UAG agonists as a novel therapeutic class, with preclinical optimization for type II diabetes and related metabolic/cardiovascular conditions.
- Other names
- Un-octanoylated ghrelinUnacylated ghrelin (diabetes)UAG agonistDiabetes therapeutic peptideTH-0332TH0332TH 0332Ghrelin inhibitor peptides
02
Targets
UAGR (Unacylated ghrelin receptor)
Beyond the preview
Go deeper on AZP-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZP-01.